VGI Health Technology Limited

Equities

VTL

AU0000152597

Biotechnology & Medical Research

End-of-day quote National Stock Exchange of Australia Other stock markets 06:00:00 2023-06-28 pm EDT			5-day change	1st Jan Change
0.02 ^AUD	-33.33%		-.--%	-.--%

Feb. 08	VGI Health Technology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI
2023	VGI Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	CI

VGI Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2022

August 09, 2022 at 09:10 pm EDT

VGI Health Technology Limited reported earnings results for the full year ended June 30, 2022. For the full year, the company reported sales was AUD 0.009705 million. Net loss was AUD 7.87 million compared to AUD 3.9 million a year ago. Basic loss per share was AUD 0.057 compared to AUD 0.0282 a year ago. Diluted loss per share was AUD 0.057 compared to AUD 0.0282 a year ago.

Latest news about VGI Health Technology Limited

VGI Health Technology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 08	CI
VGI Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-06	CI
Certain Ordinary Shares of VGI Health Technology Limited are subject to a Lock-Up Agreement Ending on 28-MAY-2023.	23-05-27	CI
VGI Health Technology Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-15	CI
VGI Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-09	CI
VGI Health Technology Limited Auditor Raises 'Going Concern' Doubt	22-08-09	CI
Certain Ordinary Shares of VGI Health Technology Limited are subject to a Lock-Up Agreement Ending on 28-MAY-2022.	22-05-27	CI
ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study	21-11-29	CI
VGI Health Technology Hires Darrell Crawford to Scientific Advisory Board	21-09-14	CI
Vgi Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2021	21-09-07	CI
Moko Social Media Limited Announces Resignations of Non-Executive Directors	16-04-17	CI
Moko Social Media Limited(ASX:MKB) dropped from S&P/ASX Emerging Companies Index	16-03-21	CI
Moko Social Media Limited Reports Unaudited Consolidated Earnings Results for the Half Year Ended 31 December 2015	16-03-01	CI
MOKO Social Media Announces Management Changes	16-02-18	CI
True Blue Media, LLC, acquired Blue Nation Review from Moko Social Media Limited.	15-11-24	CI
Moko Social Media Limited Announces Retirement of Jeff White as Director	15-11-17	CI
Moko Social Media Limited Announces Consolidated Cash Flow Results for the First Quarter Ended September 30, 2015	15-10-30	CI
Moko Social Media Limited Announces Audited Consolidated Earnings Results for the Year Ended June 30, 2015	15-10-04	CI
Moko Social Media Limited Reports Parent Earnings Results for the Year Ended 30 June 2015	15-09-30	CI
VGI Health Technology Limited Auditor Raises 'Going Concern' Doubt	15-09-29	CI
Moko Social Media Limited Appoints Diana Rhoten as Non-Executive Director with Effect from 1 October 2015	15-09-23	CI
MOKO Social Media Appoints Emma Waldon as Non-Executive Director with Effect from 1 October 2015	15-09-22	CI
Moko Social Media Limited Reports Unaudited Preliminary Consolidated Earnings Results for the Year Ended 30 June 2015	15-08-30	CI
MOKO Social Media Limited completed the acquisition of 10% stake in BigTeams, LLC for $1 million.	15-04-27	CI
Moko Social Media Limited Announces Resignation of Hans de Back, Non Executive Director	15-04-12	CI

Chart VGI Health Technology Limited

Duration

Period

More charts

Company Profile

VGI Health Technology Limited is an Australia-based biotechnology company. The Companyâs MELT3 formulation of Tocotrienols (T3s) is designed to be dissolved in the mouth and then swallowed, which is used for certain non-disease and self-limiting exercise related indications, such as reduction of delayed onset muscle soreness (DOMS), improved muscle recovery after exercise and improved maintenance of muscle power. MELT3 is designed for nutraceuticals and dietary supplements. Its TransT3, a transmucosal delivery platform for T3s, is designed to enhance absorption of the T3s by facilitating sublingual and buccal (transmucosal) absorption. T3s are absorbed into the capillaries below the sublingual and buccal mucosa and then released into the blood stream. Its Tocotrienol ProDrugs (TPD) is a prodrug delivery platform for T3s designed to enhance absorption of T3s into the lymphatic system of the gut and release of T3s into the blood stream.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VGI HEALTH TECHNOLOGY LIMITED	-.--%	1.78M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	103B
REGENERON PHARMACEUTICALS, INC.	+3.31%	96.73B
ARGENX SE	+1.66%	21.31B
BIONTECH SE	-16.16%	21.21B
GENMAB A/S	-6.82%	18.79B
WUXI APPTEC CO., LTD.	-41.41%	16.37B
BEIGENE, LTD.	-22.87%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.98B

Bio Therapeutic Drugs